sisted of 13 patients presenting with seizures only, and the third group consisted of 15 patients presenting with combined hemorrhage and seizures. An example of symptomatic CH is shown in Fig. 1 . The location of CHs varied: 49 patients had solitary lesions located in the brainstem, 39 were cortical/subcortical, 14 were in deep nuclei (thalamus and basal ganglion), 10 were in the cerebellum and/or the fourth ventricle, and 13 patients had multiple lesions (four of 13 had a family history of same). All 125 patients were treated within 6 months of the initial onset of symptoms. The mean lesion volume was 3.12 cm 3 (range 0.032-25.9 cm 3 ). The mean margin dose was 12.1 Gy (range 9-20 Gy). Every attempt was made to achieve a highly conformal dose distribution by using multiple small shots so that we could maximize the mean dose and minimize the radiation volume outside the target. After treatment, 438 MR images were obtained in the 125 patients (range one-10 images per patient). The mean clinical follow-up time was 5.4 years (range 9 months-10.2 years). Statistical comparisons were performed using the t-test and chi-square test for analysis of hemorrhage rate and risk factors, and the Student t-test and chi-square test for analysis of the seizure outcomes. A probability value of less than 0.05 was considered statistically significant.
To define the relationship between the lesion and spike sources, several patients underwent an MEG study before treatment.
Results

Rebleeding Rate
The rebleeding rate was analyzed in 112 hemorrhagic patients (97 patients in Group 1 and 15 patients in Group 3). The locations of CHs are provided in Table 1 . Before GKS, the most common clinical findings were hemiparesis in 34% of patients and cranial nerve deficits in 33% (Table 2) . After GKS, 32 rebleeding episodes occurred during the follow-up period. Patients were defined as experiencing a rebleeding episode if they presented with clinical symptoms and T 1 -and T 2 -weighted MR imaging demonstrated a hyperintense volume. Among the 32 reported rebleeding episodes, 14 occurred in the brainstem, eight in deep nucleus, six in multiple lesions, three in cortical/subcortical areas, FIG. 1. A series of MR images obtained in a 30-year-old woman who experienced seizures and hemorrhage from a mesial temporal CH. The patient was treated with GKS (margin dose 13 Gy, 50% isodose at the lesion margin). Before GKS, T 1 -and T 2 -weighted MR images revealing subacute hemorrhage (left). Magnetic resonance images at 12 months (center) and 32 months (right) after GKS, revealing marked shrinkage of the lesion. The patient became seizure free. and only one in cerebellum ( Table 1 ). The total follow-up time was 492 patient-years, and the annual rebleeding rate was 6.5% (32 episodes/492 patient-years). The 2-year cutoff point was also used for further analysis. A total of 23 rebleeding episodes were reported within the first 2 years after GKS, with a rebleeding rate of 10.3% (23 episodes/ 224 patient-years). After 2 years, only nine rebleeding episodes were reported, producing a rebleeding rate of 3.3% (nine episodes/268 patient-years). This drop in the rebleeding rate from 10.3% within 2 years to 3.3% beyond 2 years is significant (p = 0.0038). Among the 45 patients who sustained at least two bleeding episodes prior to GKS, there were 55 rebleeding episodes reported before treatment, and the follow-up time was 188 patient-years from the time of first symptomatic bleeding to the time of GKS. The rebleeding rate was 55 episodes per 188 patient-years before treatment or 29.2%. After GKS, the rebleeding rate significantly dropped from 10 episodes per 197 patient-years (5%) (p Ͻ 0.0001).
Among the patients in this study with symptomatic hemorrhages, 45 had CHs located in the brainstem, 10 had CHs located in the deep nucleus, and 13 had multiple lesions. The relationship between location and rebleeding rate almost reached statistical significance (p = 0.051). In this study, six patients had CHs associated with a venous anomaly (demonstrated by MR imaging). Although only the lesion part was treated and the venous part was spared rebleeding episodes still occurred in five patients.
Seizure Outcomes
A total of 28 patients presented with seizures. Of these 28 patients, 13 presented with seizures alone and the remaining 15 presented with seizures and hemorrhage. The locations of CHs in these patients are provided in Table 3 . The patients were classified into two groups, sporadic seizure and chronic epilepsy. Patients in the sporadic seizure group reported a seizure history of no more than 6 months before GKS (11 patients). The remaining 17 patients reported a seizure history of more than 6 months and they were defined as having chronic epilepsy. The Engel classification for evaluating the seizure outcome was used. Engel Grades I and II were defined as good outcomes. After GKS, 11 (39%) were seizure free (Engel I) and four (14%) reported only rare seizures (Engel II). Overall, 53% of patients reported having good control of their seizures (Table 4) . The achievement of a good result with sporadic seizures was 10 (91%) of 11 patients compared with four (24%) of 17 in the chronic group (p = 0.001) ( Table 5 ). Other prognostic factors such as age, lesion site, presence of combined hemorrhage, mean margin dose, and maximum dose were not associated with the seizure outcomes.
An epileptogenic focus on MEG was successfully detected in only one patient (Fig. 2) . In this patient with epileptogenic foci detected on MEG, we treated not only the lesion but also the spike sources detected; this patient became seizure free. The existence of distinct spike sources makes the delineation more difficult in treating CHs in patients with seizures.
Complications
After GKS, AREs developed in 17 (13.1%) patients; however, these were symptomatic in only three (2.5%) patients. The true complication rate of clinically significant complications was 2.5%. The only parameter to have a statistically significant relationship to the development of AREs was the maximum dose (p = 0.005). Other complications included cyst formation (one patient) and hydrocephalus (five patients). In addition to these complications, 12 patients had permanent neurological deficits, all of which were induced by rebleeding episodes.
Discussion
Rebleeding Rate
The rebleeding rate of untreated CHs has been reported by Aiba, et al., 2 to be a 23% annual risk for patients who had experienced a previous hemorrhage. In another prospective study, however, Kondziolka, et al., 14 reported the annual risk was only 4.5%. The large variation in the reports of rebleeding rates is probably caused by differences in patient selection, definition of bleeding episodes, follow-up time, mode of lesion diagnosis, and variation in the frequency of image follow up. In this study, a rebleeding episode was defined as any new or worsening neurological deficit accompanied by MR imaging-verified new hemorrhage. Based on that definition, the post-GKS annual rebleeding rate in this study was 6.5% (32 episodes/492 patient-years). There are sever- 13 (76) al factors that increase the risk of experiencing a rebleeding episode. The first is the location of the CH. Some authors reported that patients with CHs located in infratentorial area or brainstem had a higher rebleeding rate. 8, 25, 27, 28 The location of lesions that rebled in this series supports this notion. Other than location, it is conceivable that CHs associated with a venous anomaly present a higher risk of hemorrhage than do CHs alone. 1, 18, 28 The findings of this current series are also in agreement with this notion. Additionally, patients with a family history or with multiple lesions also had a higher rebleeding rate. 19, 28, 35 A major contribution to the total rebleeding rate in this series was made by three patients who experienced nine rebleeding episodes between them. One of these patients had a CH in the midbrain that was associated with a venous anomaly (Fig. 3) . The second patient had a CH in the thalamus. The third patient had multiple lesions, and the lesion with repetitive bleeding was located in pons. Nonetheless, the study demonstrated a significant reduction in the rebleeding rate after GKS, with a mean follow up of 5.4 years Our results are similar to reports in the literature in which a useful effect of GKS in CH is found. Kondziolka, et al., 15 observed a rebleeding rate of 32% in 47 patients before GKS. After GKS, the rebleeding rate dropped to 8.8% within the first 2 years and 1.1% from 2 to 6 years. Amin-Hanjani, et al., 3 reported a decrease in the rebleeding rate in 73 lesions from 17.3% per lesion per year before proton beam treatment to 10.4% after treatment. These results suggest that GKS can reduce the rebleeding rate and thus the danger of CH.
Seizure Outcome
The correlation between epilepsy and CHs has been widely reported in the literature. 4, 8, 13, 14 The epileptogenicity of these lesions resulted from the ongoing deposition of iron and blood products at the margin of the lesion. 17, 21 Several
Magnetic resonance images obtained in a 42-year-old woman with a seizure history of more than 1 year owing to a mesial temporal CH. Before GKS, the spike sources (circles) were detected on MEG and superimposed on axial (left) and coronal (right) MR imaging slices. The lesion volume was 1.6 ml, we extended the radiation volume to 3.7 ml for covering the spike sources. The patient became seizure free.
FIG. 3. Upper Left:
A T 1 -weighted MR image obtained in an 18-year-old man with a brainstem CH associated with a venous anomaly. The patient was treated with GKS (margin dose 10 Gy, 56% isodose at the lesion margin). Upper Right: Seven months after GKS, the lesion size is smaller. Lower Left: Thirty months after GKS, the patient experienced the first rebleeding episode. Lower Right: Forty-eight months after GKS, the patient experienced the second rebleeding episode with worsening of right hemiparesis.
articles on the management of CHs associated with seizures have been published, 4, 7, 21, 29, 31 and the general consensus is that microsurgical resection of the lesion is the best treatment. More recently, several authors have used GKS to treat epilepsy patients with CHs safely and effectively. 12, 29 Gamma knife surgery has been established as an alternative treatment option for patients with CHs in eloquent and inaccessible areas. Régis, et al., 29 reported the results of GKS in 49 patients with epilepsy associated with CHs and demonstrated that 53% (26 of 49) of patients were seizure free and 20% (10 of 49) of patients were significantly improved. A good result (Engel Grades I and II) was obtained in 73% of patients reported by Régis, et al. In the current study, good results (Engel Grades I and II) were achieved in 53% of patients. The duration of seizure history before treatment was the only parameter to show an association with the effect of treatment on the seizures. The results of this study are similar to the results of several epilepsy surgery studies, 7, 31 in which it was reported that patients with shorter seizure histories and fewer preoperative seizures could be more effectively treated by lesionectomy alone. In this study, most patients in the sporadic seizure group reported epilepsy combined with bleeding episodes before treatment. We hypothesize that preventing the risk of rebleeding and decreasing the deposition of blood products may play a role in the improved seizure control. Under the secondary epileptogenicity theory, 24 in patients with a longer seizure history, the primary active epileptogenic foci may lead to cortical loci of seizure onset that are anatomically distinct from the primary lesion. 7, 34 Based on this theory, some authors suggest that a wider extent of resection might be necessary in such cases. 7, 8, 31 Complication and Radiation Dose
To reduce the incidence of radiation-induced complications, most authors use a lower margin dose for treating CHs than for treating AVMs. 11, 16 Nonetheless, the optimal radiosurgery dose for treating CHs is still unknown. In this study, most CHs were deep seated or located in eloquent regions; therefore, our mean margin dose was lower than that reported by other groups. Our mean dose to the margin was 12.1 Gy. In addition the treatments were very conformal. It is suggested that only ARE-induced neurological deficits can truly reflect the complications of GKS. The low margin dose and maximal conformity was aimed at reducing these effects. On analysis the only factor associated with a risk of AREs was the maximum dose. All other complications observed in this series-permanent neurological deficits in 12 patients and hydrocephalus in five patientswere secondary to the natural course of the lesions or to the hemorrhagic episodes.
Conclusions
In this study, GKS was used to treat patients with symptomatic CHs, with a mean follow up of 5.4 years. The rebleeding rate appeared to be reduced after GKS. The seizure frequency also improved after GKS in patients with a short duration of CH-induced epilepsy. Gamma knife surgery seems to have a useful role to play in the management of selected patients with CHs.
